Press Releases Journey Medical Corporation

Equities

DERM

US48115J1097

Real-time Estimate Cboe BZX Other stock markets 09:07:50 09/05/2024 pm IST			5-day change	1st Jan Change
3.615 ^USD	+1.26%		-1.38%	-37.85%

01/05	Journey Medical Corporation Appoints Joseph M. Benesch as Chief Financial Officer	CI
21/03	Transcript : Journey Medical Corporation, 2023 Earnings Call, Mar 21, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024	07/05	AQ
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer	02/05	AQ
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024	25/04	AQ
Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	22/03	AQ
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea	18/03	AQ
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024	15/03	AQ
Journey Medical Corporation to Participate in the 36th Annual ROTH Conference	13/03	AQ
Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual Meeting	11/03	AQ
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea	05/01	AQ
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million	03/01	AQ
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea	06/12	AQ
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights	08/11	AQ
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023	31/23/31	AQ
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 vs. Solodyn	23/23/23	AQ
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)	20/23/20	AQ
Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations	06/23/06	AQ
Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights	09/23/09	AQ
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023	03/23/03	AQ
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023	19/23/19	AQ
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults	12/23/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Journey Medical Corporation

Equities

DERM

US48115J1097

Press Releases

Filters